CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Jennifer D BrooksElizabeth A ComenAnne S ReinerIrene OrlowSiok F LeongXiaolin LiangLene MellemkjærJulia A KnightCharles F LynchEsther M JohnLeslie BernsteinMeghan WoodsDavid R Doodynull nullKathleen E MaloneJonine L BernsteinPublished in: Breast cancer research : BCR (2018)
This study suggests that the CYP2D6 phenotype may contribute to some of the observed variability in the impact of tamoxifen treatment for a first breast cancer on risk of developing CBC.
Keyphrases